| REGISTERED NUMBER: |
| STRATEGIC REPORT, |
| REPORT OF THE DIRECTORS AND |
| FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| FOR |
| LEVIDIAN NANOSYSTEMS LIMITED |
| REGISTERED NUMBER: |
| STRATEGIC REPORT, |
| REPORT OF THE DIRECTORS AND |
| FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| FOR |
| LEVIDIAN NANOSYSTEMS LIMITED |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| CONTENTS OF THE FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| Page |
| Company Information | 1 |
| Strategic Report | 2 |
| Report of the Directors | 3 |
| Statement of Directors' Responsibilities | 5 |
| Report of the Independent Auditors | 6 |
| Profit & Loss Account | 10 |
| Balance Sheet | 11 |
| Statement of Changes in Equity | 12 |
| Cash Flow Statement | 13 |
| Notes to the Cash Flow Statement | 14 |
| Notes to the Financial Statements | 15 |
| LEVIDIAN NANOSYSTEMS LIMITED |
| COMPANY INFORMATION |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| DIRECTORS: |
| REGISTERED OFFICE: |
| REGISTERED NUMBER: |
| AUDITORS: |
| Chartered Accountants |
| & Statutory Auditors |
| Unit 1, Cambridge House |
| Camboro Business Park |
| Oakington Road, Girton |
| CAMBRIDGE |
| Cambridgeshire |
| CB3 0QH |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| STRATEGIC REPORT |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| The Directors, in preparing this Strategic Report, have complied with the s414c of the Companies Act 2006 which requires the Company to present a fair view of its business along with a description of the principal risks and uncertainties facing the Company. |
| REVIEW OF BUSINESS |
| The Company saw income in the year rise to £3.7m following the successful deployment of Generation 1 LOOP systems to customers in the oil and gas, wastewater treatment and agricultural industries. Geographically, these customers were in the United Kingdom, the United Arab Emirates and Europe. The Company made an operating loss of £9.2m during the year, reflecting the early-stage nature of the business. |
| PRINCIPAL RISKS AND UNCERTAINTIES |
| The management of risks is based on the balance of risk and reward, determined through careful assessment of the potential likelihood and impact: |
| The market for graphene developing more slowly than anticipated is one key risk. This is mitigated by focussing on accelerated technical applications of graphene with customers in industries that have immediate and material demand. |
| The Company faces the challenge of deploying its larger Generation 2 LOOP systems to customer sites, and this risk is mitigated by working with expert assembly partners to construct the units. |
| There is a risk that the markets for equity growth capital to fund activity remain weak. This risk has been mitigated by engaging with investors who have a clear investment thesis sponsoring graphene and hydrogen technologies and having existing investors demonstrably prepared to continue backing the Company. |
| KEY PERFORMANCE INDICATORS |
| Given the nature of the business, the Directors are of the opinion that the KPIs necessary for an understanding of the performance of the business relate to income and technology progress which are described above. |
| KEY R&D ACTIVITIES |
| During 2024, Levidian Nanosystems Limited successfully constructed its first Generation 2 LOOP system, capable of processing significantly greater volumes of gas, thereby demonstrating commercially scaled technology. The Company also achieved strong results from testing graphene in a wide range of valuable commercial applications, preparing it for future success as these opportunities convert into orders. |
| FUTURE PLANS |
| The Company will remain relentless in further scaling its technology and focussing deeply on customers with demand for the triple benefits derived from Levidian's proprietary technology, namely decarbonisation, hydrogen and graphene. |
| ON BEHALF OF THE BOARD: |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| REPORT OF THE DIRECTORS |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| The directors present their report with the financial statements of the company for the year ended 31 December 2024. |
| PRINCIPAL ACTIVITIES |
| The principal activity of Levidian Nanosystems Limited is to research, develop, scale and commercialise processing technology which can convert harmful climate gases into valuable derivative products such as hydrogen and graphene which can be used to power or enhance our customers' products. |
| DIVIDENDS |
| No dividends will be distributed for the year ended 31 December 2024. |
| EVENTS SINCE THE END OF THE YEAR |
| Information relating to events since the end of the year is given in the notes to the financial statements. |
| DIRECTORS |
| The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report. |
| Other changes in directors holding office are as follows: |
| DIRECTORS INDEMNITIES |
| As permitted by the Articles of Association, the Directors have the benefit of an indemnity which is a qualifying third party indemnity provision as defined by Section 234 of the Companies Act 2006. The indemnity was in force throughout the last financial year and is currently in force. The Company also purchased and maintained throughout the financial year Directors’ and Officers’ liability insurance in respect of itself and its Directors. |
| GOING CONCERN |
| The company incurred a loss for the year ended 31 December 2024 and anticipates that operating losses will continue for the immediate future due to investment in research and development and therefore it remains reliant on securing further funding to be able to operate for the foreseeable future. The directors have assessed the forecast spend as part of the preparation of its business plan and the availability of funding and based on the continued management of its expenditure during the next 12 month period and the likelihood of the availability of further funding, the directors consider that the company can meet liabilities as they fall due and therefore continue to adopt the going concern basis in preparing the financial statements. |
| STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS |
| So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information. |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| REPORT OF THE DIRECTORS |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| AUDITORS |
| The auditors, Staffords, will be proposed for re-appointment at the forthcoming Annual General Meeting. |
| ON BEHALF OF THE BOARD: |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| STATEMENT OF DIRECTORS' RESPONSIBILITIES |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations. |
| Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to: |
| - | select suitable accounting policies and then apply them consistently; |
| - | make judgements and accounting estimates that are reasonable and prudent; |
| - | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. |
| The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. |
| REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
| LEVIDIAN NANOSYSTEMS LIMITED |
| Opinion |
| We have audited the financial statements of Levidian Nanosystems Limited (the 'company') for the year ended 31 December 2024 which comprise the Profit & Loss Account, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). |
| In our opinion the financial statements: |
| - | give a true and fair view of the state of the company's affairs as at 31 December 2024 and of its loss for the year then ended; |
| - | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and |
| - | have been prepared in accordance with the requirements of the Companies Act 2006. |
| Basis for opinion |
| We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. |
| Conclusions relating to going concern |
| In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. |
| Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. |
| Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. |
| Other information |
| The directors are responsible for the other information. The other information comprises the information in the Strategic Report, the Report of the Directors and the Statement of Directors' Responsibilities, but does not include the financial statements and our Report of the Auditors thereon. |
| Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. |
| In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. |
| Opinions on other matters prescribed by the Companies Act 2006 |
| In our opinion, based on the work undertaken in the course of the audit: |
| - | the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and |
| - | the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements. |
| REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
| LEVIDIAN NANOSYSTEMS LIMITED |
| Matters on which we are required to report by exception |
| In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors. |
| We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: |
| - | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or |
| - | the financial statements are not in agreement with the accounting records and returns; or |
| - | certain disclosures of directors' remuneration specified by law are not made; or |
| - | we have not received all the information and explanations we require for our audit. |
| Responsibilities of directors |
| As explained more fully in the Statement of Directors' Responsibilities set out on page five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. |
| In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so. |
| REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
| LEVIDIAN NANOSYSTEMS LIMITED |
| Auditors' responsibilities for the audit of the financial statements |
| Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. |
| The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: |
| We have obtained an understanding of the legal and regulatory framework applicable to the company, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the Financial Statements. |
| We have considered the nature of the industry and sector, control environment and business framework, including the design of the company's remuneration policies. |
| We have enquired of management in regard to their own assessment of the risks of irregularities, including fraud. |
| We have obtained relevant documentation and representations in order to form an opinion on potential irregularities, including fraud. |
| We have reviewed the company's documentation of their policies and procedures relating to identifying, evaluating, and complying with laws and regulations, detecting and responding to the risks of fraud, and the internal controls established to mitigate the risks of fraud and non-compliance with laws and regulations. |
| Audit procedures performed during the audit included transaction testing with a focus on areas of judgement and estimations, and entries determined to be large or relating to unusual transactions. These audit procedures are designed to provide reasonable assurance that the Financial Statements were free from fraud or error. However, detecting irregularities that result from fraud is inherently more difficult than detecting those that result from error, as those irregularities that result from fraud may involve collusion, deliberate concealment, forgery or intentional misrepresentations. |
| No instances of non compliance with laws and regulations or of fraud were communicated to us during the audit. |
| A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors. |
| REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF |
| LEVIDIAN NANOSYSTEMS LIMITED |
| Use of our report |
| This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed. |
| for and on behalf of |
| Chartered Accountants |
| & Statutory Auditors |
| Unit 1, Cambridge House |
| Camboro Business Park |
| Oakington Road, Girton |
| CAMBRIDGE |
| Cambridgeshire |
| CB3 0QH |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| PROFIT & LOSS ACCOUNT |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 2024 | 2023 |
| Notes | £ | £ |
| TURNOVER | 3 |
| Cost of sales | ( |
) | ( |
) |
| GROSS LOSS | ( |
) | ( |
) |
| Administrative expenses | ( |
) | ( |
) |
| (10,993,922 | ) | (5,323,381 | ) |
| Other operating income |
| OPERATING LOSS | 5 | ( |
) | ( |
) |
| Interest receivable and similar income |
| LOSS BEFORE TAXATION | ( |
) | ( |
) |
| Tax on loss | 7 |
| LOSS FOR THE FINANCIAL YEAR | ( |
) | ( |
) |
| OTHER COMPREHENSIVE INCOME | - | - |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR |
( |
) |
( |
) |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| BALANCE SHEET |
| 31 DECEMBER 2024 |
| 2024 | 2023 |
| Notes | £ | £ | £ | £ |
| FIXED ASSETS |
| Intangible assets | 8 |
| Tangible assets | 9 |
| CURRENT ASSETS |
| Stocks | 10 |
| Debtors | 11 |
| Cash at bank |
| CREDITORS |
| Amounts falling due within one year | 12 |
| NET CURRENT ASSETS |
| TOTAL ASSETS LESS CURRENT LIABILITIES |
| CREDITORS |
| Amounts falling due after more than one year |
13 |
| NET ASSETS |
| CAPITAL AND RESERVES |
| Called up share capital | 15 |
| Share premium | 16 |
| Retained earnings | 16 | ( |
) | ( |
) |
| SHAREHOLDERS' FUNDS |
| The financial statements were approved by the Board of Directors and authorised for issue on |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| STATEMENT OF CHANGES IN EQUITY |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| Called up |
| share | Retained | Share | Total |
| capital | earnings | premium | equity |
| £ | £ | £ | £ |
| Balance at 1 January 2023 | ( |
) |
| Changes in equity |
| Issue of share capital | - |
| Total comprehensive income | - | ( |
) | - | ( |
) |
| Balance at 31 December 2023 | ( |
) |
| Changes in equity |
| Total comprehensive income | - | ( |
) | - | ( |
) |
| Balance at 31 December 2024 | ( |
) |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| CASH FLOW STATEMENT |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 2024 | 2023 |
| Notes | £ | £ |
| Cash flows from operating activities |
| Cash generated from operations | 1 | ( |
) | ( |
) |
| Tax refund |
| Net cash from operating activities | ( |
) | ( |
) |
| Cash flows from investing activities |
| Purchase of intangible fixed assets | ( |
) | ( |
) |
| Purchase of tangible fixed assets | ( |
) | ( |
) |
| Sale of tangible fixed assets |
| Interest received |
| Net cash from investing activities | ( |
) | ( |
) |
| Cash flows from financing activities |
| Capital repayments in year |
| Share issue |
| Net cash from financing activities |
| (Decrease)/increase in cash and cash equivalents | ( |
) |
| Cash and cash equivalents at beginning of year |
2 |
7,433,679 |
| Cash and cash equivalents at end of year | 2 | 2,879,294 | 13,014,752 |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| NOTES TO THE CASH FLOW STATEMENT |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 1. | RECONCILIATION OF LOSS BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS |
| 2024 | 2023 |
| £ | £ |
| Loss before taxation | ( |
) | ( |
) |
| Depreciation charges |
| Profit on disposal of fixed assets | ( |
) |
| Finance income | (45,610 | ) | (51,624 | ) |
| (9,219,282 | ) | (4,927,987 | ) |
| Decrease/(increase) in stocks | ( |
) |
| (Increase)/decrease in trade and other debtors | ( |
) |
| Increase in trade and other creditors |
| Cash generated from operations | ( |
) | ( |
) |
| 2. | CASH AND CASH EQUIVALENTS |
| The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts: |
| Year ended 31 December 2024 |
| 31/12/24 | 1/1/24 |
| £ | £ |
| Cash and cash equivalents | 2,879,294 | 13,014,752 |
| Year ended 31 December 2023 |
| 31/12/23 | 1/1/23 |
| £ | £ |
| Cash and cash equivalents | 13,014,752 | 7,433,679 |
| 3. | ANALYSIS OF CHANGES IN NET FUNDS |
| Other |
| non-cash |
| At 1/1/24 | Cash flow | changes | At 31/12/24 |
| £ | £ | £ | £ |
| Net cash |
| Cash at bank | 13,014,752 | (10,135,458 | ) | 2,879,294 |
| 13,014,752 | ( |
) | 2,879,294 |
| Debt |
| Finance leases | (162,013 | ) | (401,663 | ) | 259,058 | (304,618 | ) |
| (162,013 | ) | (401,663 | ) | 259,058 | (304,618 | ) |
| Total | 12,852,739 | (10,537,121 | ) | 259,058 | 2,574,676 |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| NOTES TO THE FINANCIAL STATEMENTS |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 1. | STATUTORY INFORMATION |
| Levidian Nanosystems Limited is a |
| 2. | ACCOUNTING POLICIES |
| Basis of preparing the financial statements |
| Preparation of consolidated financial statements |
| The financial statements contain information about Levidian Nanosystems as an individual company, and do not contain consolidated financial information as the parent of a group. The company is exempt under S402 of the Companies Act 2006 from the requirements to prepare consolidated accounts on the basis that the inclusion of subsidiaries is not material for the purpose of giving a true and fair view. |
| Critical accounting judgements and key sources of estimation uncertainty |
| In the assumption of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and other associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. |
| The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. |
| Turnover |
| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
| Turnover from the sale of goods is recognised when the company has transferred the significant risks and rewards of ownership to the buyer and it is probable that the company will receive the previously agreed upon payment. These criteria are considered to be met when the goods are despatched to the buyer. |
| Patents and licences |
| Patents and licences are being amortised evenly over their useful economic life of twenty years. |
| Development costs |
| Development costs comprise expenditure on the development of Generation 2 LOOP Systems. These costs will be amortised over the useful economic life of the Generation 2 LOOP Systems.once the development phase has been completed. |
| Tangible fixed assets |
| Leasehold property | - |
| Plant and machinery | - |
| Tangible fixed assets are stated at historical cost less accumulated depreciation and any accumulated impairment losses. |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 2. | ACCOUNTING POLICIES - continued |
| Stocks |
| Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. |
| Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition. |
| Going concern |
| The company incurred a loss for the year ended 31 December 2024 and anticipates that operating losses will continue for the immediate future due to investment in research and development and therefore it remains reliant on securing further funding to be able to operate for the foreseeable future. The directors have assessed the forecast spend as part of the preparation of its business plan and the availability of funding and based on the continued management of its expenditure during the next 12 month period and the likelihood of the availability of further funding, the directors consider that the company can meet liabilities as they fall due and therefore continue to adopt the going concern basis in preparing the financial statements. |
| Impairment reviews |
| The carrying values of tangible fixed assets are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable. |
| 3. | TURNOVER |
| The turnover and loss before taxation are attributable to the principal activities of the company. |
| In the opinion of the directors, the company only has one class of business, and the geographical markets supplied do not differ substantially from each other. |
| 4. | EMPLOYEES AND DIRECTORS |
| 2024 | 2023 |
| £ | £ |
| Wages and salaries |
| Social security costs |
| Other pension costs |
| The average number of employees during the year was as follows: |
| 2024 | 2023 |
| Operations | 53 | 32 |
| Business development and Marketing | 12 | 10 |
| Finance, Administration and Management | 15 | 10 |
| 2024 | 2023 |
| £ | £ |
| Directors' remuneration |
| Directors' pension contributions to money purchase schemes |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 4. | EMPLOYEES AND DIRECTORS - continued |
| Information regarding the highest paid director is as follows: |
| 2024 | 2023 |
| £ | £ |
| Emoluments etc |
| Pension contributions to money purchase schemes |
| 5. | OPERATING LOSS |
| The operating loss is stated after charging/(crediting): |
| 2024 | 2023 |
| £ | £ |
| Depreciation - owned assets |
| Profit on disposal of fixed assets | ( |
) |
| Patents and licences amortisation |
| Foreign exchange differences |
| Research and Development |
| 6. | AUDITORS' REMUNERATION |
| 2024 | 2023 |
| £ | £ |
| Fees payable to the company's auditors for the audit of the company's financial statements |
18,067 |
10,426 |
| 7. | TAXATION |
| Analysis of the tax credit |
| The tax credit on the loss for the year was as follows: |
| 2024 | 2023 |
| £ | £ |
| Current tax: |
| UK corporation tax | ( |
) |
| Tax on loss | ( |
) |
| The tax credit relates to tax repaid as a result of a claim under the R&D tax relief scheme for SME's. |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 8. | INTANGIBLE FIXED ASSETS |
| Patents |
| and | Development |
| licences | costs | Totals |
| £ | £ | £ |
| COST |
| At 1 January 2024 |
| Additions |
| At 31 December 2024 |
| AMORTISATION |
| At 1 January 2024 |
| Amortisation for year |
| At 31 December 2024 |
| NET BOOK VALUE |
| At 31 December 2024 |
| At 31 December 2023 |
| 9. | TANGIBLE FIXED ASSETS |
| Leasehold | Plant and |
| property | machinery | Totals |
| £ | £ | £ |
| COST |
| At 1 January 2024 |
| Additions |
| At 31 December 2024 |
| DEPRECIATION |
| At 1 January 2024 |
| Charge for year |
| At 31 December 2024 |
| NET BOOK VALUE |
| At 31 December 2024 |
| At 31 December 2023 |
| 10. | STOCKS |
| 2024 | 2023 |
| £ | £ |
| Stocks |
| Work-in-progress |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 11. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2024 | 2023 |
| £ | £ |
| Trade debtors |
| Other debtors |
| VAT |
| Prepayments and accrued income |
| 12. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
| 2024 | 2023 |
| £ | £ |
| Finance leases (see note 14) |
| Trade creditors |
| Social security and other taxes |
| Other creditors |
| Accruals and deferred income |
| 13. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |
| 2024 | 2023 |
| £ | £ |
| Finance leases (see note 14) |
| 14. | LEASING AGREEMENTS |
| Minimum lease payments fall due as follows: |
| Finance leases |
| 2024 | 2023 |
| £ | £ |
| Net obligations repayable: |
| Within one year |
| Between one and five years |
| Non-cancellable |
| operating leases |
| 2024 | 2023 |
| £ | £ |
| Within one year |
| Between one and five years |
| In more than five years |
| Lease payments during the year recognised as an expense totalled £26,000 (2023:£26,000). |
| LEVIDIAN NANOSYSTEMS LIMITED (REGISTERED NUMBER: 08186993) |
| NOTES TO THE FINANCIAL STATEMENTS - continued |
| FOR THE YEAR ENDED 31 DECEMBER 2024 |
| 15. | CALLED UP SHARE CAPITAL |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2024 | 2023 |
| value: | £ | £ |
| £0.001 Ordinary | 0.1p | 110 | 110 |
| 33,000 | £0.001 Preferred | 0.1p | 33 | 33 |
| 143 | 143 |
| Each Ordinary Share is entitled to one vote in any circumstances. Each Ordinary share is entitled pari passu to dividend payments. In the event of any liquidation, dissolution or winding up, each ordinary share is entitled pari passu to participate in the distribution of the assets available for distribution to ordinary shareholders. The Ordinary Shares are not redeemable or liable to be redeemed at the option of the company or the shareholder. |
| Each Preferred Share is entitled to one vote in any circumstances, each preferred share is entitled pari passu to dividend payments. In the event of any liquidation, dissolution or winding up, each preferred share is entitled to receive (prior and in preference to any distribution to the ordinary shareholders), the issue price of such preferred shares plus all accrued but unpaid dividends on such preferred share. The preferred shares are not redeemable or liable to be redeemed at the option of the company or the shareholder. |
| 16. | RESERVES |
| Retained | Share |
| earnings | premium | Totals |
| £ | £ | £ |
| At 1 January 2024 | ( |
) | 16,643,787 |
| Deficit for the year | ( |
) | ( |
) |
| At 31 December 2024 | ( |
) | 8,188,363 |
| 17. | RELATED PARTY DISCLOSURES |
| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group. |
| During the year, a total of key management personnel compensation of £ |
| 18. | POST BALANCE SHEET EVENTS |
| After the year end, but prior to the approval of the Financial Statements, the company has issued a further 5,500 Preferred Shares to an exiting investor, for consideration of £5,000,000. |
| 19. | ULTIMATE CONTROLLING PARTY |
| The Ultimate Controlling Party is Mr James Somerset Edmiston, by virtue of his holding of the majority of the issued share capital. |
| 20. | SHARE INCENTIVE SCHEMES |
| As at 31 December 2024, 10,280 options from the total pool of 11,000 were issued, had vested and were exercised early in 2025. 420 further options were issued and had vesting dates of 20th July 2025 (390) and 9th January 2026 (30). 300 remaining options are committed to employees and will be issued when relevant tax paperwork has been finalised. |